Mohit Manrao, SVP, Head of US Oncology AstraZeneca, shared on LinkedIn:
“This content is for US audiences only:
AstraZeneca announced that the FDA has approved our perioperative immunotherapy combination in muscle-invasive bladder cancer (MIBC) for patients who are ineligible for, or have declined, cisplatin-based chemotherapy.
This approval is based on results from the VOLGA Phase III trial which showed that our novel regimen nearly halved the risk of disease recurrence and reduced the risk of death by 42 percent.
Why it matters.
Patients with MIBC often face disease recurrence, even after standard-of-care bladder removal surgery. VOLGA offers a new option that may be beneficial for this population, driving IO-based treatment approaches and offering hope to patients and their families.
Our team continues expanding our leadership in bladder cancer care as VOLGA joins NIAGARA and POTOMAC as the third approved bladder cancer indication in less than two years.
What’s next.
We’re energized by this news and looking forward to bringing this innovative regimen to eligible patients who may benefit.”

You may also be interested in:
Mohit Manrao Announces AstraZeneca’s New Biomarker Testing Awareness Campaign
FDA Approves Durvalumab Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancer
